Page 8 - Dr Reddy’s Laboratories

Dr Reddy's says it aims to cut greenhouse gas emissions by 55% by 2030

Dr Reddy's Laboratories on Monday said it has committed to reduce its greenhouse gas emissions by 55 per cent by 2030. The Hyderabad-based drug major has joined hands with the Science Based Targets initiative (SBTi), thus becoming the first Indian and the third Asian pharmaceutical company to have set its science-based targets to further minimise environmental impact, Dr Reddy's Laboratories said in a statement. The company has committed to reducing its Scope 1 and 2 greenhouse gas (GHG) emissions by 55 per cent by 2030 from 2017-18 base year, which are in line with the latest climate science of limiting global warming to below 1.5C above pre-industrial levels, it added. "Continuous improvement in our environmental performance is a notable aspect of our sustainability journey. We are delighted to join SBTi in taking a science-based approach to set our GHG emission reduction targets and accelerating our efforts to creating a positive impact on our planet," Dr Reddy's Laboratories ...

Dr Reddy's yet to apply for clinical trials of Sputnik V Covid-19 vaccine

Sources further added that there were no plans for any emergency-use authorisation of the Sputnik V without relevant and convincing local data

Covid-19: Dr Reddy's to distribute Russian vaccine in India. What we know

While Dr Reddy's Labs is preparing for clinical trials of Sputnik V, major manufacturers in the country are sceptical about the drug

Covid-19: Mass production of Sputnik V likely to take several months

Vaccine makers here feel the Sputnik is still a work in progress and needs time to develop

Top headlines: Dr Reddy's to get Russia vaccine, airlines' Q1 revenue dips

Business Standard brings you the top headlines of the day

Russia to sell Covid-19 vaccine to India's Dr. Reddy's Laboratories

The Russian Direct Investment Fund added that it had agreed to cooperate on clinical trials and the distribution of the vaccine with the Indian firm

Slew of new drug launches, patent victory to drive Dr Reddy's US business

Ongoing pace of product launches in the US should lead to stronger growth after a good Q1, say analysts

Dr Reddy's launches generic arthritis drug Diclofenac Sodium in US market

Dr Reddy's Laboratories on Wednesday said it has launched over-the-counter Diclofenac Sodium topical gel, used for arthritis pain, in the US market

Dr Reddy's launches Remdesivir for coronavirus treatment in India

Dr Reddys Laboratories Ltd on Wednesday announced the launch of Remdesivir, meant for treatment of COVID-19 patients, under a brand name 'Redyx' in India

Wockhardt reports net profit at Rs 760 cr for June qtr on exceptional items

Drug firm Wockhardt on Saturday reported a consolidated net profit of Rs 759.75 crore for June quarter mainly on account of exceptionalitems in connection with the transfer of a business comprising 62 products and Baddi facility toDr Reddy's Laboratories. The company had posted a net loss of Rs 36.88 crore for April-June 2019-20, Wockhardt said in a filing to BSE. Total income stood at Rs 606.22 crore in the quarter under review. It was Rs 733.66 crore in the year-ago period, the filing added. Wockhardt launchednew chemical entity (NCE) during the quarterin the Indian pharma market. Products have been launched under the tablet and injection category under the brand name 'Emrock O and Emrock', the filing said. The focus on strategic R&D initiatives of the company in the global arena continued to remain one of the key priorities,itadded. It said that divestment of business undertaking to Dr Reddy's Laboratories was accomplished during the quarter and Rs 1,483 crore has been received

Dr Reddy's Labs launches Wilson's disease treatment capsules in US

Pharma major Dr Reddy's Laboratories said it has launched generic Penicillamine capsules, used for treatment of Wilson's disease and cystinuria, in the US market

Dr Reddy's forays into hospital nutrition with Celevida Maxx in India

Dr Reddys Laboratories Ltd announced its entry into the hospital nutrition segment with the launch of 'Celevida Maxx' in India

DRL launches Avigan for mild Covid-19 infections at Rs 99 a tablet

Drug to be imported from Japan for time being, India manufacturing to start soon

Dr Reddy's launches Avigan (Favipiravir) in India for coronavirus

Dr Reddy's Laboratories Ltd announced the launch of Avigan (Favipiravir) 200 mg tablets in India

Covid-19 drug sales shine even as domestic pharma market slows down

Major therapy areas show decline or low single-digit growth

Dr Reddy's to launch Covid drugs remdesivir and favipiravir in August

Trying to boost acquired Wockhardt portfolio which saw sharp decline in sales during pandemic

Dr Reddy's: Strong Q1 show in spite of disruption lifts sentiment

Normalising US and India sales likely to drive earnings in FY21

Trailing in the value chain: Domestic pharma's unfinished agenda

In the first of a 5-part series, we look at reasons keeping Indian pharma sector from becoming the best globally

Performance may be quite volatile in FY21 due to coronavirus: Dr Reddy's

The company however remains cautiously optimistic of re-calibrating its levers to suit the new business environment, it noted

Covid-19 treatment: Dr Reddy's partners with Fujifilm, GRA for favipiravir

Dr Reddy's will herewith establish a setup for manufacturing drugs of the same quality as Avigan, and utilize GRA's global sales network to supply the manufactured drugs swiftly and in a stable manner